Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Melanoma Genes

Financiado

Cerrado

Gene Discovery in Melanoma Progression and Therapeutic Resistance

Melanoma is among the most common and deadly human cancers. It kills more than 2000 people in the UK every year but an effective cure for metastatic disease does not exist yet. The mutation of valine to glutamic acid at position 6... ver más

14/04/2014

GRL

210K€

Presupuesto del proyecto: 210K€

Líder del proyecto

GENOME RESEARCH LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-04-14 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

GRL

0.00€ | Lider

CR-UK

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Hairy Cell Leukemia Genetics driven targeted therapy of Hairy Cell Leukemia 2M€ Cerrado

2MoveMate4Melanoma A treatment for BRAF inhibitor resistant melanoma 150K€ Cerrado

PDC2022-133569-I00 DESARROLLO DE UN BIOMARCADOR DE LA RESPUESTA TERAPEUTICA DEL... 150K€ Cerrado

ZF-MEL-CHEMBIO Chemical Biology in Zebrafish Drug Leads and New Targets in... 2M€ Cerrado

TRIBBLES Characterizing the clinical relevance and the mechanism und... 161K€ Cerrado

SAF2015-63638-R PROTEINAS SCAFFOLD COMO MODULADORES DE LA RESISTENCIA A INHI... 472K€ Cerrado

Líder del proyecto

GENOME RESEARCH LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 210K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Melanoma is among the most common and deadly human cancers. It kills more than 2000 people in the UK every year but an effective cure for metastatic disease does not exist yet. The mutation of valine to glutamic acid at position 600 (V600E) of the BRAF kinase is found in over 60% of human melanomas, establishing it as a prominent oncogene in melanoma. Since this mutation is also commonly identified in benign and dysplastic nevi, the hypothesis is that additional mutations are required to induce melanomagenesis. Thus, a first challenge in the field is to identify those genetic events cooperating with oncogenic BRAFV600E in melanoma development, and exploit novel targets for combinatorial therapies. Furthermore, the discovery of a central role for the BRAFV600E mutation in melanoma has led to the development of BRAFV600E-specific drug inhibitors. Initial clinical trials report extremely promising tumour regressions in the majority of patients. However, all patients eventually relapse after several months of treatment as a result of acquired resistance. I postulate that the therapeutic inhibition of BRAFV600E alone allows tumour cells to acquire additional yet unknown mutations that finally induce drug resistance and cancer’s regrowth. Therefore a second challenge is to understand the genetic determinants and molecular mechanisms responsible for the drug resistance to BRAFV600E inhibitors, which currently represent the most promising treatment option for melanoma. The aim of this project is to use novel mouse models of melanoma that develop in the setting of a Sleeping Beauty insertional mutagenesis to identify (i) genes cooperating with oncogenic BRAFV600E to promote melanoma and (ii) genes accountable for the development of drug resistance against BRAFV600E inhibitors. Overall, the expected results in understanding the mechanisms of both melanomagenesis and resistance to BRAFV600E inhibitors will provide novel opportunities to develop effective melanoma therapeutics.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores